Synergy Pharmaceuticals Культура компании

Dr. Gary S. Jacob, Ph.D., has been Executive Chairman of Synergy Pharmaceuticals, Inc. since July 2008 and served as its Chief Executive Officer and President from September 2013 to December 2017. Dr. Jacob served as the Chief Executive Officer of Callisto Pharmaceuticals Inc. since May 2003 until January 2013. He served as Secretary of TrovaGene, Inc. since February 2009. He served as the Chief Executive Officer and President of ContraVir Pharmaceuticals, Inc. from May 15, 2013 to March 19, 2014. Dr. Jacob served as an Acting Chief Executive Officer and President of Pawfect Foods Inc. since July 2008. He served as an Acting Chief Executive Officer of Callisto Pharmaceuticals, Inc. He served as the Chief Scientific Officer of Synergy Pharmaceuticals Inc. from 1999 to 2003. He has been the Chairman of ContraVir Pharmaceuticals, Inc. since March 19, 2014 and its Director since May 15, 2013. From 1990 to 1998, he served as a Monsanto Science Fellow, specializing in the field of Glycobiology. From 1997 to 1998, Dr. Jacob served as Director of Functional Genomics, Corporate Science & Technology, Monsanto. He has been an Independent Director of TrovaGene, Inc. since February 2009. He served as the Chairman of Synergy Pharmaceuticals, Inc. from October 2003 to November 2011. He has been a Director of Synergy Pharmaceuticals Inc. since July 2008. He served as an Executive Director of Callisto Pharmaceuticals, Inc. since October 2004 until January 2013. From 1990 to 1997, he served as a Director of Glycobiology, G.D. Searle Pharmaceuticals Inc. From 1986 to 1990, he served as Manager of the G.D. Searle Glycobiology Group located at Oxford University, England. He served as a Director of Pawfect Foods, Inc. since July 2008. Dr. Jacob holds Ph.D. in Biochemistry from the University of Wisconsin-Madison. He holds BS in Chemistry from University of Missouri-Columbia.

Dr. Patrick H. Griffin, M. D., FACP, has been the Chief Medical Officer of Synergy Pharmaceuticals, Inc. since May 29, 2013 and has been its Executive Vice President since January 19, 2015. Dr. Griffin served as an Executive Director of Synergy Pharmaceuticals, Inc. Dr. Griffin served as the Chief Medical Officer and Senior Vice President of Development at ImmusanT, Inc. He is a board-certified physician in both internal medicine and gastroenterology and came to ImmusanT from his most recent position as Head of External Innovation for Sanofi's immuno-inflammation therapeutic strategy unit, where he had a particular focus on therapeutic approaches to autoimmunity through immune system modulation. He originally joined Sanofi in 2005 as a Senior Director, Clinical Development in the area of internal medicine. Previously, he held positions of increasing responsibility in clinical development at Forest Laboratories. After completed an internship and residency in internal medicine at Presbyterian Hospital in New York City and fellowship in gastroenterology at Brigham and Women's Hospital in Boston, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held academic clinical research, teaching and management positions. He worked several years in the solo private practice of internal medicine and gastroenterology in New York City before he moved to industry. Dr. Griffin is a Fellow of the American College of Physicians. He received his medical degree from Columbia University.

Dr. Kunwar Shailubhai, also known as Shailu, Ph.D., M.B.A., has been Chief Executive Officer and Chief Scientific Officer at Tiziana Life Sciences PLC since June 12, 2017. Dr. Shailubhai has been Chief Executive Officer of Rasna Therapeutics, Inc. since April 14, 2017. Dr. Shailubhai is a Co-Founder of Synergy Pharmaceuticals Inc., and has been its Chief Scientific Officer since July 9, 2008 and Executive Vice President since November 21, 2015. He has been Executive Director at Tiziana Life Sciences PLC since June 12, 2017. Dr. Shailubhai served as the Senior Vice President of Drug Discovery at Synergy Pharmaceuticals Inc. from March April 6, 2004 to July 2008. He served as Head of Research and Development at Callisto Pharmaceuticals, Inc. (Formerly, Webtronics Inc.) and also served its Executive Vice President of Research and Development from May 2003 to March 2004 and Executive Vice President. From 2001 to April 2003, Dr. Shailubhai served as the Vice President for Drug Discovery of Synergy Pharmaceuticals Inc., where he was chiefly responsible for the preclinical development of GC-C agonist program for drugs to treat colon cancer and GI inflammation. He served as Chief Scientific Officer of Pawfect Foods Inc. since July 2008. From 1993 to 2000, he served at Monsanto Life Sciences Company as Group Leader of the Cancer Chemoprevention Group and was involved in several cancer research projects. He has extensive experience within the life sciences sector, drawing on 30 years of experience in research and development of drug candidates for treatment of gastrointestinal disorders, inflammatory diseases and cancers. He has been a Non-Executive Director of West African Minerals Corporation since July 6, 2017. He has been Director of Rasna Therapeutics, Inc. since August 2016. Dr. Shailubhai served as a Non-Executive Director at Tiziana Life Sciences PLC since January 22, 2015 until June 14, 2017. He served as a Director of GenSignia Life Sciences Inc. Dr. Shailubhai's pioneering research programme culminated in the development of the drug Trulance??? (plecanatide) which received FDA approval in January 2017 for the treatment of adults with chronic idiopathic constipation. A supplemental new drug application has been submitted for FDA review of Trulance for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). He has more than 20 issued patents and over 50 peer-reviewed publications. He previously served as a Senior Staff Fellow at the National Institutes of Health and as an Assistant Professor at the University of Maryland. Dr. Shailubhai holds Ph.D. in Microbiology in 1984 from the University of Baroda, India and an M.B.A. in 2001 from the University of Missouri, St. Louis.

Marianne Jackson serves as the SVP, Sales and Market Access for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP). Marianne started at Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) in January of 2016. Marianne is based in the Greater Philadelphia Area.

Pam Cebulski serves as the SVP Marketing for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP). Pam started at Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) in October of 2015. Pam is based in the Greater Philadelphia Area.

Kevan Clarke serves as the Senior Regional Business Director for Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Kevan started at Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) in December of 2016. Kevan is based in the Greater Boston Area.

Gary Gemignani serves as the EVP, Chief Financial Officer for Synergy Pharmaceuticals Inc.. Gary started at Synergy Pharmaceuticals Inc. in April of 2017. Gary is based in the Greater New York City Area.

Leslie Magnus serves as the Senior Vice President, Medical Affairs of Synergy Pharmaceuticals Inc.. Leslie currently resides in the Greater New York City Area.

Greg Kresge serves as the Vice President Procurement of Synergy Pharmaceuticals Inc.. Greg currently resides in the Greater Philadelphia Area.